Functional dissociation between proforms and mature forms of proteinase 3, azurocidin, and granzyme B in regulation of granulopoiesis

Exp Hematol. 2002 Jul;30(7):689-96. doi: 10.1016/s0301-472x(02)00816-0.

Abstract

Objective: We previously demonstrated that secreted proform(s) of the neutrophil serine protease PR3 (proteinase 3) can down-modulate the fraction of normal human colony-forming unit granulocyte-macrophage (CFU-GM) in S-phase, whereas PR3 extracted from mature neutrophils lacks this ability. The objective of this study was to characterize the structural and functional dissociation between secreted proforms and granule-stored mature forms and to extend the investigation to other related hematopoietic serine proteases.

Materials and methods: Conditioned media containing secreted proteases from transfectant cell lines with stable expression of human PR3, neutrophil elastase, cathepsin G, azurocidin, and granzymes A, B, H, K, and M were tested for their ability to reduce the fraction of normal human CFU-GM in S phase. Furthermore, recombinant PR3, azurocidin, and granzyme B with defined N-terminal propeptides, and the respective mature forms without propeptide, were functionally characterized.

Results: In addition to PR3, secreted proforms of azurocidin and granzymes A, B, H, K, and M, but not cathepsin G or neutrophil elastase, have S-phase reducing activity. This activity is restricted to the dipeptide proforms, whereas mature forms without propeptide have no S-phase reducing activity. On the other hand, only the mature forms of PR3 and granzyme B could bind the serine protease inhibitor diisopropylfluorophosphate (DFP), or aprotinin in the case of azurocidin. We also demonstrate that granulocyte colony-stimulating factor-stimulated CD34+ cells and interleukin-2-stimulated lymphocytes secrete active proforms of PR3 and granzyme B, respectively.

Conclusion: These results demonstrate distinctive functional and conformational differences between proforms and mature forms of these hematopoietic serine proteases and suggest novel growth regulatory mechanisms in granulopoiesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimicrobial Cationic Peptides
  • Aprotinin / pharmacology
  • Blood Cells / drug effects
  • Blood Proteins / chemistry
  • Blood Proteins / metabolism
  • Blood Proteins / physiology*
  • Bone Marrow Cells / drug effects
  • Bone Marrow Cells / metabolism
  • Carrier Proteins / chemistry
  • Carrier Proteins / metabolism
  • Carrier Proteins / physiology*
  • Cathepsins / metabolism
  • Cell Division / drug effects
  • Cells, Cultured / drug effects
  • Colony-Forming Units Assay
  • Culture Media, Conditioned / pharmacology
  • Cytoplasmic Granules / metabolism
  • Granulocyte Colony-Stimulating Factor / pharmacology
  • Granulocytes / cytology*
  • Granzymes
  • Hematopoiesis / physiology*
  • Hematopoietic Stem Cells / enzymology*
  • Hematopoietic Stem Cells / metabolism
  • Hematopoietic Stem Cells / ultrastructure
  • Humans
  • Interleukin-2 / pharmacology
  • Isoflurophate / pharmacology
  • Kidney / cytology
  • Leukocyte Elastase / metabolism
  • Myeloblastin
  • Protein Conformation
  • Protein Precursors / chemistry
  • Protein Precursors / metabolism
  • Protein Precursors / physiology*
  • Recombinant Fusion Proteins / physiology
  • S Phase / drug effects
  • Sequence Deletion
  • Serine Endopeptidases / chemistry
  • Serine Endopeptidases / metabolism
  • Serine Endopeptidases / physiology*
  • Serine Proteinase Inhibitors / pharmacology
  • Transfection

Substances

  • AZU1 protein, human
  • Antimicrobial Cationic Peptides
  • Blood Proteins
  • Carrier Proteins
  • Culture Media, Conditioned
  • Interleukin-2
  • Protein Precursors
  • Recombinant Fusion Proteins
  • Serine Proteinase Inhibitors
  • Isoflurophate
  • Granulocyte Colony-Stimulating Factor
  • Aprotinin
  • Cathepsins
  • GZMB protein, human
  • Granzymes
  • Serine Endopeptidases
  • Leukocyte Elastase
  • Myeloblastin